絞り込み

17363

広告

福岡・大牟田の浸水4mに、防災科研解析…「線状降水帯」相次いで発生 (読売新聞)

防災科学技術研究所(茨城県つくば市)は6日夜、九州北部の大雨で、福岡県大牟田市では浸水の深さが少なくとも4メートルに達したとの解析結果を発表した。 防災科研は、...

  1. [企業] Dragonfly社が5500...
  2. コロナ 3か月以上闘病の米 俳優が死去
  3. 障害者雇用に関する優良な中小事業主に対す...
  4. 新型コロナウイルスに関連した患者等の発生...

ニュース一覧

Aflibercept for exudative AMD with persistent fluid on ranibizumab and/or bevacizumab.

著者 Cho H , Shah CP , Weber M , Heier JS
Br J Ophthalmol.2013 Jun 13 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

Department of Retina, Ophthalmic Consultants of Boston, Boston, Massachusetts, USA.

スターを付ける スターを付ける     (928view , 0users)

Full Text Sources

OBJECTIVE: To investigate the effect of aflibercept 2.0 mg in cases resistant to ranibizumab 0.5 mg and/or bevacizumab 1.25 mg treatment. PURPOSE: To evaluate the anatomic and visual effect of intravitreal aflibercept 2.0 mg in cases of exudative age-related macular degeneration (AMD) with persistent fluid on optical coherence tomography (OCT) despite regular ranibizumab 0.5 mg and/or bevacizumab 1.25 mg treatment at 1 and 6 months. METHODS: Retrospective review at Ophthalmic Consultants of Boston, Boston, Massachusetts, USA of exudative AMD cases with persistent fluid on regular ranibizumab 0.5 mg and/or bevacizumab 1.25 mg treatment switched to intravitreal aflibercept 2.0 mg treatment and followed for 6 months. Tabulated data included details of prior treatments, best available visual acuity, central subfoveal thickness on registered spectral domain OCT before and after aflibercept injection centred on the anatomic fovea and macular description before and after aflibercept injection. RESULTS: A total of 353 eyes with exudative AMD were switched to aflibercept during the study period. Of these, 28 eyes in 28 patients had persistent fluid after an average of 20 regular ranibizumab/bevacizumab injections (range 7-37). At 1 month, 89% (25 eyes) showed anatomic improvement and 18% (five eyes) were dry after a single aflibercept injection. Central subfoveal thickness improved from 295 to 272 microns (p<0.001) after one aflibercept injection. After an average of 4.4 aflibercept injections (range 3-6) over 6 months, the central subfoveal thickness remained improved (274 microns, p=0.008); 64% (18 eyes) showed anatomic improvement and a quarter of eyes (25%, seven eyes) were dry. Visual acuity did not improve at 1 month (logarithm of minimum angle of resolution (logMAR) 0.54, Snellen 20/69, p=0.64) or 6 months (logMAR 0.57, Snellen 20/76, p=0.49). Treatment was well tolerated with no adverse events reported. CONCLUSIONS: A significant proportion of exudative AMD cases with persistent fluid on OCT despite regular ranibizumab 0.5 mg and/or bevacizumab 1.25 mg treatment respond anatomically to aflibercept 2.0 mg. Visual acuity did not improve. Aflibercept may be beneficial anatomically in cases of exudative AMD treated with persistent fluid on ranibizumab and/or bevacizumab.
PMID: 23766432 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード